Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is developing innovative approaches that help modulate the immune system to combat, ocular, fibrosis and Cytokine release syndrome. The Company recently released topline results from a Phase III trial of Reproxalap being developed for the treatment of dry eye syndrome....
Nemaura Medical, Inc. (NASDAQ: NMRD), a medical device technology Company developing innovative non-invasive wearable diagnostic devices, announced the official launch of BEAT®diabetes, and the availability of proBEAT™, a non-invasive, daily-wear adhesive glucose monitor. The device comes along a proBEAT™ monitor, a first-in-class non-invasive, daily-wear glucose...
Galera Therapeutics (NASDAQ: GRTX), a clinical–stage Biopharmaceutical Company aiming to redefine radiotherapy in cancer, announced positive interim results from a phase 1/2 trial of GC4419 or avasopasem manganese. An investigational, highly selective small molecule superoxide dismutase mimetic, GC4419 has the potential to convert superoxide to...
Zelira Therapeutics (OTCQB: ZLDAF), a biopharmaceutical Company developing cannabinoid-based formulations for the treatment of a wide range of medical conditions, announced full enrollment in its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment for non-cancer pain. The study intends to evaluate the...
Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...
ChromaDex (NASDAQ: CDXC), a nutraceutical Company focussed on improving the way people age, announced the launch of a “first-of-its-kind” Phase 1 clinical study to test the safety, efficacy and potential of branded nicotinamide riboside (NR), Niagen, in improving the effects of exercise therapy in older...
The American Academy of Ophthalmology defines cataract as the clouding of the lens through which light rays are refracted and is characterized by blurry or unclear vision, double images, sensitivity to light, difficulty in seeing well at night and seeing dull or faded color instead...
Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company leveraging its proprietary Genome5000™ program to develop therapeutics for the treatment of disease such as diabetes, metabolism, oncology and neuropathic pain, announced that the Food and Drug Administration (FDA) has reiterated its rejection of the Company’s New Drug...
Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...
Provention Bio (NASDAQ: PRVB), a clinical-stage biopharmaceutical Company, announced the grant of a PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA), for PRV-031 (teplizumab), indicated for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease....
